GSK pays $1.2bn for liver drug as it culls TIGIT programme

GSK pays $1.2bn for liver drug as it culls TIGIT programme

GSK decided to abandon a TIGIT-targeted drug for cancer this week, then hatched a plan to replace it with a candidate for liver disease MASH

GSK to buy liver disease drug for $1.2B

With its purchase of Boston Pharmaceuticals' drug, GSK extends a streak of dealmaking it's undertaken to build a liver disease franchise.

GSK to buy experimental MASH drug for $1.2B upfront

The deal for Boston Pharmaceuticals' efimosfermin will help the U.K. drugmaker shore up its pipeline of future medicines.

GSK to Buy Liver Disease Drug For as Much as $2 Billion

GSK Plc agreed to buy an experimental medicine to treat liver disease for as much as $2 billion as the UK drugmaker seeks to shore up its pipeline of new medicines.

GSK to pay $1.2B upfront to snag Boston Pharma’s mid-stage MASH hope

GSK will hand over $1.2 billion in upfront cash to license a closely-watched candidate for fatty liver disease from Boston Pharmaceuticals. The drug in question is Boston Pharma’s lead asset, efimosfermin alfa. Previously known as ...

GSK to spend $2bn on Phase III liver disease drug acquisition - Pharmaceutical Technology

The deal comes at a time of revival into liver disease treatment investment as market opportunity beckons.